menu
    • menu

    Find Perfluorohexyloctane manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    6

    API Suppliers

    API Suppliers

    2

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    4

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    5

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    2

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    13DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    6

    US Patents

    1

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    16

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 133331-77-8, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane, Perfluorohexyloctane, 7vyx4elwqm, Perfluorohexyloctane [who-dd], 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane
    Molecular Formula
    C14H17F13
    Molecular Weight
    432.26  g/mol
    InChI Key
    WRYIIOKOQSICTB-UHFFFAOYSA-N
    FDA UNII
    7VYX4ELWQM
    Perfluorohexyloctane
    1 2D Structure

    Perfluorohexyloctane

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
    2.1.2 InChI
    InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
    2.1.3 InChI Key
    WRYIIOKOQSICTB-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCCCCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    7VYX4ELWQM
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. F6h8 Cpd

    2. Perfluorhexyl-octan

    3. Perfluorohexyl-octan

    4. Perfluorohexyloctane

    2.3.2 Depositor-Supplied Synonyms

    1. 133331-77-8

    2. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

    3. Perfluorohexyloctane

    4. 7vyx4elwqm

    5. Perfluorohexyloctane [who-dd]

    6. 1,1,1,2,2,3,3,4,4,5,5,6,6,-tridecafluorotetradecane

    7. 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane F 6h8

    8. Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-

    9. Starbld0000620

    10. Unii-7vyx4elwqm

    11. 1-(tridecafluorohexyl)octane

    12. Schembl890448

    13. Dtxsid20440585

    14. Mfcd07784188

    15. Akos015911101

    16. Zinc100046937

    17. Bs-20913

    18. Cs-0205555

    19. A806597

    20. J-006351

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 432.26 g/mol
    Molecular Formula C14H17F13
    XLogP38.7
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count13
    Rotatable Bond Count11
    Exact Mass432.1122666 g/mol
    Monoisotopic Mass432.1122666 g/mol
    Topological Polar Surface Area0 Ų
    Heavy Atom Count27
    Formal Charge0
    Complexity464
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    API SUPPLIERS

    read-more
    read-more

    01

    Metrochem API Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39428

    Submission : 2024-04-30

    Status : Active

    Type : IV

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40173

    Submission : 2024-07-01

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Mankind Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Micro Labs Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Micro Labs Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

    Details:

    MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: Miebo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 12, 2023

    blank

    01

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

    Details : MIEBO (perfluorohexyloctane ophthalmic solution) is used for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation.

    Brand Name : Miebo

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 12, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of Dry Eye Disease ...

    Details:

    Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: NOV'03

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: SENJU PHARMACEUTICAL CO LTD

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement June 13, 2023

    blank

    02

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : SENJU PHARMACEUTICAL CO LTD

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Opht...

    Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...

    Brand Name : NOV'03

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    June 13, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dr...

    Details:

    Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: Miebo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Novaliq

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 18, 2023

    blank

    03

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Novaliq

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solut...

    Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.

    Brand Name : Miebo

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 18, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

    Details:

    NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: 37926

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Novaliq

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 04, 2023

    blank

    04

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Novaliq

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloct...

    Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...

    Brand Name : 37926

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 04, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)

    Details:

    NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: 37926

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Novaliq

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 06, 2022

    blank

    05

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Novaliq

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 ...

    Details : NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

    Brand Name : 37926

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 06, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)

    Details:

    NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: 37926

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Novaliq

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 07, 2022

    blank

    06

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Novaliq

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatmen...

    Details : NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.

    Brand Name : 37926

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 07, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research ...

    Details:

    NOV03 (perfluorohexyloctane) is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: 37926

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 03, 2022

    blank

    07

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (...

    Details : NOV03 (perfluorohexyloctane) is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

    Brand Name : 37926

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 03, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalm...

    Details:

    Presentations include results from Phase 3 trials of investigational NOV03 (perfluorohexyloctane), as well as from several studies involving products from company's consumer health care, pharmaceutical and surgical portfolios, such as XIPERE for suprachoroidal use.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: NOV03

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 28, 2022

    blank

    08

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs Duri...

    Details : Presentations include results from Phase 3 trials of investigational NOV03 (perfluorohexyloctane), as well as from several studies involving products from company's consumer health care, pharmaceutical and surgical portfolios, such as XIPERE for supracho...

    Brand Name : NOV03

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 28, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Catara...

    Details:

    The data show that NOV03, (perfluorohexyloctane) met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: NOV03

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Bausch & Lomb Incorporated

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2022

    blank

    09

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (P...

    Details : The data show that NOV03, (perfluorohexyloctane) met both primary endpoints of total Corneal Fluorescein Staining, a measure that assesses damage to the eye, and visual analogue scale dryness score at day 57.

    Brand Name : NOV03

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 25, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 3 Trial of SHR8058 Eye Drops (Perfluorohexyloctane) Conducted by Jiangsu Hengrui Pharmaceuticals in The People’s Republic of China Shows Statist...

    Details:

    Company provided update on phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease associated with Meibomian gland dysfunction and the trial met its prespecified primary sign endpoint improvement of total corneal fluorescein staining.


    Lead Product(s): Perfluorohexyloctane

    Therapeutic Area: Ophthalmology Brand Name: SHR8058

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 16, 2021

    blank

    10

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Novaliq

    Germany
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Perfluorohexyloctane

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Phase 3 Trial of SHR8058 Eye Drops (Perfluorohexyloctane) Conducted by Jiangsu Hengrui Pharmaceuti...

    Details : Company provided update on phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease associated with Meibomian gland dysfunction and the trial met its prespecified primary sign endpoint improvement of total corneal fl...

    Brand Name : SHR8058

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    December 16, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    india-flag.png
    Perfluorohexyloctane (50 kg) API needed in India [ENA19843]
    A leading pharmaceutical company with over three decades of experience in manufacturing of active ingredients & intermediates is looking for suppliers of Perfluorohexyloctane (50 kg) API for development purposes. The suppliers must support this enquiry with CoA.
    01 Jul 2024

    Reply

    01 Jul 2024

    Reply text-arrow

    Reply Comment (2)

    01 Jul 2024

    Bangladesh.png
    Perfluorohexyloctane API needed in Bangladesh [ENA19834]
    A company that focuses on trading of various pharmaceutical, food, medical devices & chemical products is looking for suppliers of Perfluorohexyloctane API for commercial purposes. The suppliers must support this enquiry with CoA.
    01 Jul 2024

    Reply

    01 Jul 2024

    Reply text-arrow

    Reply Comment (1)

    01 Jul 2024

    india-flag.png
    Injectable Grade Perfluorohexyloctane API needed in India [ENA19586]
    A company that focuses on research, development and manufacturing of APIs and FDFs is looking for suppliers of Injectable Grade Perfluorohexyloctane API for both commercial & development purposes. The required quantity is 70 kg for development & 200 kg to exhibit batches. The suppliers must support this enquiry with CoA.
    27 May 2024

    Reply

    27 May 2024

    Reply text-arrow

    Reply Comment (2)

    27 May 2024

    Bangladesh.png
    Perfluorohexyloctane (200 kg) API needed in Bangladesh [ENA18608]
    A company that deals in the distribution of various pharmaceutical products is looking for suppliers of Pharma Grade Perfluorohexyloctane (200 kg) API for commercial purposes. The suppliers must support this enquiry with GMP, CoA and stability data.
    13 Nov 2023

    Reply

    13 Nov 2023

    Reply text-arrow

    Reply Comment (1)

    13 Nov 2023

    Pakistan.png
    Perfluorohexyloctane (100 kg - 125 kg) API needed in Pakistan [ENA18564]
    A company that focuses on developing, manufacturing and marketing of branded generic & specialty drugs in respiratory, dermatology, anti-inflammatory, anesthetics, anti-infectives, anti-nauseants, anti-emetics, anti-ulcers, NSAIDs and ophthalmics therapeutic areas is looking for suppliers of Perfluorohexyloctane (100 kg - 125 kg) API for both development & commercial purposes. The suppliers must support this enquiry with DMF, GMP & CoA.
    07 Nov 2023

    Reply

    07 Nov 2023

    Reply text-arrow

    Reply Comment (3)

    07 Nov 2023

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2037-06-21

    PERFLUOROHEXYLOCTANE

    US Patent Number : 10507132

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216675

    Patent Use Code : U-1900

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2037-06-21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2033-09-12

    PERFLUOROHEXYLOCTANE

    US Patent Number : 10449164

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216675

    Patent Use Code : U-1900

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-09-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2033-09-12

    PERFLUOROHEXYLOCTANE

    US Patent Number : 10369117

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216675

    Patent Use Code : U-1900

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-09-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2033-09-12

    PERFLUOROHEXYLOCTANE

    US Patent Number : 10058615

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216675

    Patent Use Code : U-1900

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-09-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2036-09-29

    PERFLUOROHEXYLOCTANE

    US Patent Number : 11357738

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 216675

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2036-09-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    BAUSCH AND LOMB INC

    PERFLUOROHEXYLOCTANE

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    BAUSCH AND LOMB INC

    Canada
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2033-09-12

    PERFLUOROHEXYLOCTANE

    US Patent Number : 10576154

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 216675

    Patent Use Code : U-1900

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-09-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search